Amgen (AMGN) Q4 2025 (USD): Adj. EPS 5.29 (exp. 4.73), Revenue 9.87bln (exp. 9.47bln)
Importance
Level 1
- Operating income 4.0bln (exp. 3.64bln).
Outlook
- FY adj. EPS 21.60-23.00 (exp. 22.13).
- FY revenue 37-38.4bln (exp. 37.2bln).
- FY26 share repurchases not to exceed USD 3bln.
- To initiate phase 3 studies of maritide in people living with type 2 Diabetes in 2026
#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#AMGEN INC#AMGN.US#FOREX#EQUITIES#METALS#ASIAN SESSION#US SESSION#BIOTECHNOLOGY#METALS & MINING#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#AMGN#DXY#US EQUITIES